Alendronate is a potent bisphosphonate that increases the bone mineral density of the hip, spine, and total body 21,22 and lowers the incidence of vertebral, hip, and forearm fractures by Osteoporosis is a common problem that causes your bones to become abnormally thin, weakened, and easily broken (fractured)
N Engl J Med
However, the efficacy and safety of alendronate in preventing GIOP remains controversial
Use of parathyroid hormone is promising
Applies to the following strengths: 35 mg; 70 mg; 40 mg; 5 mg; 10 mg; 70 mg/75 mL Usual Adult Dose for: Osteoporosis Prevention of Osteoporosis Paget's Disease Additional dosage information: Renal Dose Adjustments Liver Dose Adjustments Precautions Dialysis Take the medicine on an empty stomach
Alendronate is used to treat and prevent osteoporosis (a condition in which the bones become thin and weak and break easily) in women who have undergone menopause (''change of life,'' end of menstrual periods) and to treat osteoporosis in men
Go to: Visual Abstract Go to: Abstract Lymphoma patients often receive high glucocorticoid doses as part of standard therapy
Electromagnetic fields: a novel prophylaxis for steroid-induced osteonecrosis
SIESTA was a single-center, randomized, double-blinded, phase 2 study of lymphoma patients planned for glucocorticoid-containing chemotherapy
Interestingly, differently than what was observed with Abstract
This leads to an increased risk of fragility fractures (fractures resulting from low-level trauma)
Alendronate is given as 35 mg once weekly for the prophylaxis of osteoporosis in postmenopausal females and as 70 mg once weekly for the treatment of osteoporosis in men and women
B
The objective of the SIESTA trial was to determine if primary prophylaxis with oral alendronate (ALN) is safe and effective against (GIO) in lymphoma patients Alendronate ( Bisphosphonates ) 29 Pharmacology for Nursing
This study addressed the question of whether fracture healing in the context of osteoporosis prophylaxis is improved with estrogen (E) or alendronate (ALN)
Sensation of heat on the surface of the cast
bone pain, muscle or joint pain
Observational studies have shown a substantial risk of glucocorticoid-induced osteoporosis (GIO) with associated fractures
2 Further developments led to the introduction of new generations of BPs, which are characterized by their long Lymphoma patients often receive high glucocorticoid doses as part of standard therapy
Oral alendronate 5 or 10 mg/day produces sustained increases in bone mineral density (BMD) in postmenopausal women with or without osteoporosis, in men with primary osteoporosis and in both men and Studies of long-term use of bisphosphonates
Alendronate helps to reduce the risk of fracture in people with osteoporosis and some other bone conditions
However, rare adverse drug reactions may be uncovered during postmar-keting surveillance
This treatment is well tolerated
The registration was based on daily dosing of 10 mg/day
1 Treatment of Osteoporosis in Postmenopausal W omen On the other hand, data supporting bisphosphonates is more robust
A subsequent clinical trial reported that the once-weekly dosing Alendronate is generally well tolerated
After randomization, patients received weekly ALN 70 mg or placebo for a total of 52 weeks
11
Osteoporosis is caused by the cumulative effect of bone resorption in excess of bone formation
Women are at a higher risk for
Alendronate for the prevention and treatment of glucocorticoid-induced
10 mg orally once a day or 70 mg orally once a week
Fosamax, Binosto (alendronate) dosing, indications, interactions, adverse effects, and more Limitation of Use Optimal duration of use not determined; for patients at low-risk for
Key Points Oral alendronate is a safe and effective primary prophylaxis against loss in bone mineral density in lymphoma patients
(MSD Korea) 1, 10, 35, 40, 70 mg (PO) Osteoporosis, Paget's disease: Fosamax Plus D: 70 mg (PO) Osteoporosis:
Alendronate is given as 35 mg once weekly for the prophylaxis of osteoporosis in postmenopausal females and as 70 mg once weekly for the treatment of osteoporosis in men and women
- Bisphosphonates
All women 65 years and older should be screened for osteoporosis with dual energy x-ray absorptiometry of the hip and lumbar spine
For patients with these underlying cardiac conditions, prophylaxis is recommended for all dental procedures that involve manipulation of gingival tissue or the periapical region of teeth or perforation of the oral mucosa
As a substantial fraction of lymphoma patients become long-term survivors, studies that focus on mitigating the negative effects of treatment toxicities on survivorship are important
Prophylaxis and treatment of postmenopausal This study addressed the question of whether fracture healing in the context of osteoporosis prophylaxis is improved with estrogen (E) or alendronate (ALN)
However, Oral alendronate is a safe and effective primary prophylaxis against loss in bone mineral density in lymphoma patients and should be considered as a first line treatment for patients with lymphoma
(PPI) and histamine H2 receptor antagonists (H2RAs) are frequently prescribed in the prophylaxis of GI adverse effects in chronic alendronate users
Musty odor noted from cast
Comparison of alendronate vs alendronate plus mechanical loading as prophylaxis for osteoporosis in lung transplant recipients: a pilot study
osteoporosis secondary prophylaxis in patients with recent low-trauma hip fracture, osteoporosis because of corticosteroids (treatment and prophylaxis), Paget’s disease
we advise a more aggressive approach to prophylaxis: acetaminophen 650 mg 1 hour before the infusion, then every
To determine the efficacy of bisphosphonate therapy combined with the osteogenic stimulus of mechanical loading, 30 lung transplant recipients (LTRs) were randomly assigned either to alendronate (10 mg/day; n = 10), alendronate (10 mg/day) + resistance exercise (n = 10) or to a control group (n = 10)